News Search Results
Jun 07, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jun 06, 2025, 18:12 ET NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina
Carolina, Vice Chair Rozo started in Raleigh where she discussed the state of the NC biotechnology industry with leaders from the North Carolina Biotechnology Center (NCBiotech) before meeting with Co-Chairs of the NC General Assembly's Life Sciences Caucus. She also joined
More news about: National Security Commission on Emerging Biotechnology
Jun 06, 2025, 16:05 ET Spyre Therapeutics Announces Grants of Inducement Awards
June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience
More news about: Spyre Therapeutics, Inc.
Jun 06, 2025, 07:00 ET Meala Partners with dsm-firmenich to Commercialize Texturizing Protein for Meat Alternatives
PB Pea, is a clean-label texturizer produced using biotechnology. Protected by two patents, it consolidates the functionality of multiple components into a single, versatile ingredient that delivers unmatched
More news about: Meala
Jun 06, 2025, 06:55 ET Biodefense Market worth $1.81 billion by 2030 - Exclusive Report by MarketsandMarkets™
detection systems, and next-generation decontamination technologies to anticipate future biological threats. Also, the region is experiencing growth in biotechnology R&D, cross-border health security efforts, and government-backed biodefense programs. The growth of local biotech and med-tech firms is also
More news about: MarketsandMarkets
Jun 06, 2025, 06:08 ET GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of
More news about: GenEditBio
Jun 06, 2025, 02:00 ET HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey),
More news about: HTL Biotechnology
Jun 06, 2025, 02:00 ET HTL 바이오테크놀로지, 무균 히알루론산 생산 라인 신설
폴리뉴클레오티드)를 개발하고 책임감 있는 바이오 제조를 선도하는 프랑스 생명공학 기업이다. 이러한 바이오 폴리머는 의료 기업들이 안과학, 피부과, 미용 의학, 류마티스학 등 다양한 주요 분야의 치료법 개발에 활용하고 있다. HTL 바이오테크놀로지는 HTL 바이오테크놀로지 이노베이션(HTL Biotechnology Innovation Inc., HTL BII - 뉴저지)를 통해 세계적 수준의 과학 연구 센터에서 재조합 인간 콜라겐 III형(rhCOL3)을 포함한 재조합 단백질 플랫폼을 인수함으로써, 제약 등급 바이오 폴리머 개발 분야에서 세계 선도 기업으로서의 입지를 더욱 강화했다.
More news about: HTL Biotechnology
Jun 05, 2025, 23:52 ET YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's
More news about: YolTech Therapeutics
Jun 05, 2025, 16:01 ET AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jun 05, 2025, 15:03 ET Conexwest Expands Single-Phase Cold Storage Lineup: Versatile Solutions for Diverse Temperature Needs
complex electrical infrastructure. With temperature ranges from -20°F to +70°F, they are ideal for industries such as food services, pharmaceuticals, biotechnology, and agriculture.Key Features: Available in 20ft and 40ft sizesTemperature range: -20°F
More news about: Conexwest
Jun 05, 2025, 10:30 ET Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR | MarketsandMarkets™
market uptake during the studied period. By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth
More news about: MarketsandMarkets
Jun 05, 2025, 10:08 ET bitBiome Announces Strategic Partnership with Leading CMO for Manufacturing and Supply of Products
TOKYO, June 5, 2025 /PRNewswire/ -- bitBiome, Inc., a biotechnology company unlocking the potential of our planet's microbes to power the future of the bioeconomy, today announced a new partnership that will enable
More news about: bitBiome
Jun 05, 2025, 09:00 ET QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines
SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised
More news about: QureBio Ltd.
Jun 05, 2025, 09:00 ET Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Power regulation (Law Decree No. 21/2012) for Scinai's option to acquire 100% of the share capital and voting rights of Pincell S.r.l., an Italian biotechnology company.
More news about: Scinai Immunotherapeutics Ltd.
Jun 05, 2025, 08:30 ET BioDlink Strengthens Global Compliance with Argentina GMP Certification
fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of "innovation + internationalization", At the same time, it explores the extensive application of biotechnology in the field of general health,
More news about: BioDlink Biopharm Co., Ltd.
Jun 05, 2025, 08:00 ET HTL Biotechnology inaugure une nouvelle ligne de production dédiée à l'acide hyaluronique stérile
dermatologie, l'esthétique médicale et la rhumatologie. HTL Biotechnology a récemment renforcé sa position de leader mondial dans le développement de biopolymères de qualité pharmaceutique en acquérant, par l'intermédiaire de sa filiale HTL Biotechnology Innovation Inc. (HTL BII - New
More news about: HTL Biotechnology
Jun 05, 2025, 08:00 ET Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
June 5, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient has been dosed in a Phase 1b
More news about: Kazia Therapeutics Limited
Jun 05, 2025, 07:30 ET Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
increased burden for healthcare systems. About Elgan Pharma Elgan Pharma is a late-stage clinical stage, neonatology-focused biotechnology company, dedicated to developing safe, tailored therapies to address medical complications and developmental challenges that are common in preterm
More news about: Elgan Pharma; Chiesi Group
Jun 05, 2025, 07:05 ET REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
and independence, required support for breathing, cardiomyopathy and premature death. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jun 05, 2025, 07:00 ET Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer
More news about: Mediar Therapeutics
Jun 05, 2025, 06:30 ET Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced
More news about: Immunic, Inc.
Jun 05, 2025, 06:00 ET Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results
clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution
More news about: Waterdrop Inc.
Jun 04, 2025, 19:00 ET Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding
DIEGO, June 4, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256,
More news about: Rakuten Medical, Inc.
Jun 04, 2025, 16:59 ET Dynavax Comments on Glass Lewis Recommendation
as Dynavax has delivered 203% total return to stockholders over the last five years2 while vaccine peers returned 9% and the S&P Biotechnology Select Industry Index declined 17% over the same period.Dynavax is one of the few vaccine companies that has returned
More news about: Dynavax Technologies